Sage Therapeutics (SAGE) executive Shiferman gave up 79 shares at $5.48 to cover taxes or an exercise price
Insider transactions reported
Gregory L. Shiferman (executive at Sage Therapeutics Inc., SAGE) reported that they gave up 79 shares at $5.48 to cover taxes or an exercise price on Dec 24, 2024. After these transactions the filing shows 19,888 shares held directly.
- Reporting person
- Shiferman Gregory L.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 24, 2024 | Shares withheld for taxes or exercise price (F) | Common Stock1 | -79 | $5.48 | $433 | 19,888 direct |
Holdings before and after
- Common Stock: 19,967 to 19,888 direct
Footnotes from the filing
- 1. On December 24, 2024, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.
Transaction codes in this filing
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Shiferman report in this SAGE Form 4?
Gregory L. Shiferman (executive at Sage Therapeutics Inc., SAGE) reported that they gave up 79 shares at $5.48 to cover taxes or an exercise price on Dec 24, 2024. After these transactions the filing shows 19,888 shares held directly.
How many SAGE shares does Shiferman hold after this filing?
The filing shows 19,888 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code F mean on an SEC Form 4?
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
Historical context for SAGE
Earlier insider filings at SAGE
- Nov 14, 2024Chief Operating Officer Benecchi Christopher was granted 6,250 shares, increasing direct ownership by 34% to 24,737 units (SEC Form 4)
- Nov 1, 2024Officer Shiferman Gregory L. was granted 5,000 shares, increasing direct ownership by 33% to 19,967 units (SEC Form 4)
- Aug 7, 2024Chief Medical Officer Gault Laura was granted 13,500 shares and covered exercise/tax liability with 3,288 shares, increasing direct ownership by 1,945% to 10,737 units (SEC Form 4)
- Aug 7, 2024President and CEO Greene Barry E was granted 50,400 shares and covered exercise/tax liability with 12,273 shares, increasing direct ownership by 81% to 85,067 units (SEC Form 4)
- Aug 7, 2024CFO & Treasurer Iguchi Kimi was granted 13,500 shares and covered exercise/tax liability with 3,636 shares, increasing direct ownership by 14% to 81,405 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Follow SAGE and get a push notification the moment its next story breaks.